Table
Group
l.
Summary of thyroid abnormalities in the Marshallese, 1981.
(Corrected = matched control value
Est.
thy.
Total nodules
Correc-
ts
Rongelap
<10
10-18
>18
Total
22
12
33
67
17
3.
3
23
77.3
25.0
9.1
34.3
4.7
17.4
1.2
28.5
2
28.6
26.0
4
6
36.4
31.6
28.5
35.8
19
3
7
29
65.5
23.1
15.9
33.7
62.8
15.5
8.0
27.9
i
1
2
4
3.4
7.7
4.5
4,7
2.5
7.7
3.8
4.0
3
3
4.7
14.2
5.2
6.7
1
1
1.6
4.8
0.7
4.8
9.2
6.7
17
9.1
4.6
3.
1.8
1.1
4.6
275-450
190
135
217 av.
Rong. + Ail.
<10
29°
10-18
13.
>18
44
Total
86
275-1150
190- 810
135- 335
482 av.
Utirik
<10
10-18
64
21
60-95
30-60
Total
164
51 av.
>18
79°
30
9
11.4
3.5
4.5
8.3
6.1
6.0
ted %
3.6
8.3
5.4
5.2
No.
%
ted %
3
13.6
13.6
4
7
11.8
10.4
11.9
10.1
Total
lesions
Correc-
No.
1
1
2
4
%
Hypofunction**
Correc-
No. dose, rad
Ailingnae
<10
7
10-18
1
>18
ll
Total
19
No.
Carcinoma
Correc-
age 1954
810-1150T
335- 810
335
556 av.
ted %
subtracted.)}*
ted %
88.0
17.4
13.2
38.7
26.0
1
1.3
i
1
9.0
5.2
8.8
3.0
37.3
30.8
3
10.3
10.3
9
8
11.4
9.3
(Jl.
9.0
73.1
15.5
19.1
36.9
0.6
3.5
Matched controls, unexposed
<10
10-18
>18
Total
229
79
292
600
6
6
23
35
2.6
7.6
7.9
5.8
2
1
2
5
4.9
1.3
Q.7
0.8
1
\
2
1.3
0.3
0.3
2.6TT
8.9
8.2
6.2
“The cancer estimates are possibly underestimated since all unoperated nodules
were considered benign for these calculations. Occult carcinomas were not
included under carcinoma.
**No nodule cases with hypofunction are included.
(See Tables 1 and 2, Appendix
IV.)
tThe lower dose estimates for the <10 group were used for in utero cases.
TTNo correction necessary.
-59 -